GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biophytis SA (OTCPK:BPTSY) » Definitions » Notes Receivable

Biophytis (Biophytis) Notes Receivable : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Biophytis Notes Receivable?

Biophytis's Notes Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.


Biophytis Notes Receivable Historical Data

The historical data trend for Biophytis's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biophytis Notes Receivable Chart

Biophytis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biophytis Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biophytis Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Biophytis Notes Receivable Related Terms

Thank you for viewing the detailed overview of Biophytis's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Biophytis (Biophytis) Business Description

Traded in Other Exchanges
Address
BC 9, Batiment A 4eme etage, 4 pace Jussieu, Sorbonne University, Paris, FRA, 75005
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.